Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Isotope & Radiation (FRA:5IR) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
China Isotope & Radiation Forward PE Ratio Related Terms
China Isotope & Radiation Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation Forward PE Ratio Chart
China Isotope & Radiation Annual Data
Trend
Forward PE Ratio
China Isotope & Radiation Semi-Annual Data
Forward PE Ratio
FRA:5IR vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, China Isotope & Radiation's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's Forward PE Ratio falls into.
China Isotope & Radiation Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
China Isotope & Radiation (FRA:5IR) has a Forward PE Ratio of 8.79 as of Aug. 28, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on China Isotope & Radiation and its competitors. According to the industry distribution chart, China Isotope & Radiation ranks #64 out of 391 companies in the Medical Devices & Instruments industry, placing it in the top 16.4%.
Is China Isotope & Radiation's Forward PE Ratio too high?
China Isotope & Radiation's current Forward PE Ratio is 8.79. The Medical Devices & Instruments industry median Forward PE Ratio is 20.22. China Isotope & Radiation's value of 8.79 is 56.5% below this industry median. Based on the distribution chart, China Isotope & Radiation ranks #64 out of 391 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, China Isotope & Radiation has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Isotope & Radiation's Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, China Isotope & Radiation ranks #64 out of 391 companies for Forward PE Ratio. This places China Isotope & Radiation in the top 16% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 20.22. China Isotope & Radiation's value of 8.79 is 56.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 20.22, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Isotope & Radiation's current Forward PE Ratio of 8.79 is 56.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on China Isotope & Radiation and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 20.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Isotope & Radiation's current Forward PE Ratio is 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Isotope & Radiation stock overvalued right now?
China Isotope & Radiation (FRA:5IR) has a current Forward PE Ratio of 8.79. The stock's GF Value™ is €1.63, compared to a current price of €1.77 — trading 8.6% above its estimated fair value. The current Forward PE Ratio is 8.79 and 56.5% below the Medical Devices & Instruments industry median of 20.22. China Isotope & Radiation's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For China Isotope & Radiation (FRA:5IR), the current Forward PE Ratio is 8.79 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Isotope & Radiation (FRA:5IR) Overvalued in 2026?
Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued.
The current stock price of €1.77 is trading 8.6% above its estimated GF Value™ of €1.63.
Key valuation signals for FRA:5IR:
Forward PE Ratio: 8.79
GF Value™: €1.63 vs. price of €1.77 (8.6% above fair value)
Industry Position: 56.5% below the Medical Devices & Instruments median (#64 of 391)
No single metric tells the full story. See the FRA:5IR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
92GF Score
Get the complete analysis for FRA:5IR
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5IR has been successfully added to your 
